StockTipsArenaBeta

BUY Blue Star — Prakash Gaba

BUYBlue Star

byPrakash GabaHorizon: NA (inferred Swing (≤2wk))11 Sept 2026via CNBC Awaaz.

Entry₹1,560Inferred
Target₹1,650
Total upside +5.77%
Stop loss₹1,540-1.28% risk
CMP₹1,5581d ago
Active-0.13%+5.91%upside left 12d left
Follow Prakash Gaba for new calls(29% target hit, 203 closed calls)Get alertsWatch BLUESTARCO for new buy/sell callsGet alertsSee 2 other Swing calls on BLUESTARCOSee 314 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 13 Sept, 6:13 am IST
3 supporting3 neutral3 opposing
Supports the BUY call (3)

MACD above its signal line — bullish momentum

Technicals · macd·13 Sept · today

1 advisor has an active short-term BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·11 Sept · yesterday

2 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·11 Sept · yesterday

Neutral / worth noting (3)

Somerset-backed Cyrix Healthcare acquires Blue Star’s medtech business

NewsGoogle News·7 Sept · 5d ago

(opens in new tab)

Cyrix Healthcare acquires Blue Star E&E's MedTech Solutions business

NewsGoogle News·5 Sept · 1w ago

(opens in new tab)

Cyrix Healthcare acquires Blue Star E&E’s MedTech business

NewsGoogle News·4 Sept · 1w ago

(opens in new tab)
Weighs against the BUY call (3)

Blue Star sees no Q2 margin recovery as raw material costs bite

NewsGoogle News·8 Sept · 4d ago

(opens in new tab)

Blue Star Share Price Falls 2.33%: Technicals, Valuation

NewsGoogle News·8 Sept · 4d ago

(opens in new tab)

Blue Star Reports Ongoing Q2 Challenges Amid Input Price Inflation

NewsGoogle News·8 Sept · 4d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.